This segment focuses on the research and development of small molecule therapeutics designed to treat cancer by modulating the immune system. Key activities include preclinical studies, clinical trials (Phase 1 and beyond), and regulatory submissions. The company utilizes advanced medicinal chemistry and pharmacology to identify and optimize drug candidates. The primary therapeutic areas are solid tumors, with a focus on liver cancer (HCC) and other cancers. The company's lead product candidates, TPST-1495 and TPST-1120, are designed to target key pathways involved in tumor immune evasion. The company aims to improve patient outcomes by providing novel treatment options with the potential for improved efficacy and reduced side effects compared to existing therapies. Market positioning is based on the development of first-in-class therapies. Partnerships with Roche are in place to advance clinical trials. Future opportunities include expanding the clinical development of existing programs and exploring new targets within the immuno-oncology space.